NCT04227275 A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer Status TERMINATED Phase PHASE1
NCT04223765 Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Status RECRUITING Phase PHASE1
NCT04220684 Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML Status COMPLETED Phase PHASE1
NCT04217278 A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT04214886 CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04205838 Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Status TERMINATED Phase PHASE2
NCT04205240 Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Status TERMINATED Phase PHASE2
NCT04196491 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) Status COMPLETED Phase PHASE1
NCT04196413 GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) Status RECRUITING Phase PHASE1
NCT04195633 Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Status RECRUITING Phase PHASE2
NCT04191187 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Status COMPLETED Phase PHASE2
NCT04173988 Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase EARLY_PHASE1
NCT04171843 A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma Status TERMINATED Phase PHASE1
NCT04162756 Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies Status APPROVED_FOR_MARKETING Phase N/A
NCT04160195 T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Status TERMINATED Phase PHASE1
NCT04151706 CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML Status COMPLETED Phase PHASE2
NCT04146298 Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT04135092 Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab Status NO_LONGER_AVAILABLE Phase N/A